Healthtech funding in H1 2026
European Healthtech startup funding raised during H1 2026.
In H1 2026, 234 European Healthtech companies closed 237 funding rounds and raised €4.1B in equity funding (excluding debt and grants), up 3.5% versus H1 2025. Debt rounds added €181M. UK led by capital raised, and High-Tech Gründerfonds (HTGF) was the most active investor. Data as of 20 Nov 2026.
Equity funding
€4.1B
+3.5% vs H1 2025 · excl. debt & grants · +€181M debt
Funding rounds
237
-0.8% vs H1 2025
Companies
234
Top country
UK
Rank among sectors
#5
8.9% of sector funding
Debt financing
€181M
4.2% of total
Top-10 round share
58.7%
of disclosed capital
Rounds ≥ €100M
3
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, H1 2026 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jan | €850M | 51 |
| Feb | €446M | 40 |
| Mar | €279M | 42 |
| Apr | €253M | 35 |
| May | €2.0B | 33 |
| Jun | €486M | 36 |
Top countries
by € raisedHealthtech — top countries by capital, H1 2026 — interactive chart.
Data table
| Healthtech — top countries by capital, H1 2026 | |
|---|---|
| UK | €2.6B |
| France | €402M |
| Germany | €319M |
| Switzerland | €219M |
| Netherlands | €195M |
| Spain | €195M |
| Ireland | €114M |
| Iceland | €100M |
Stage mix
by € raisedHealthtech — stage mix, H1 2026 — interactive chart.
Data table
| Healthtech — stage mix, H1 2026 | |
|---|---|
| Series B | €2.1B |
| Other | €732M |
| Series A | €440M |
| Series D+ | €298M |
| Series C | €277M |
| Debt | €181M |
| Seed | €169M |
| Grant | €61M |
| Growth/Late | €57M |
| Pre-Seed | €22M |
| Crowdfunding | €233k |
Exits & M&A
17 Acquisition17 exits · €1.0B disclosed.
| Saga Diagnostics | Acquisition | Apr 2026 | €504M |
| Kaia Health | Acquisition | Jan 2026 | €239M |
| Gleamer | Acquisition | Mar 2026 | €230M |
Top deals
largest disclosed rounds in H1 2026| Company | Stage | Date | Amount |
|---|---|---|---|
| Isomorphic Labs | Series B | May 2026 | €1.8B |
| Oviva | Series D+ | Jan 2026 | €200M |
| Alvotech | Debt | Jan 2026 | €100M |
| CeQur | Series D+ | Jun 2026 | €86M |
| Ona Therapeutics | Series B | Jun 2026 | €74M |
| DentalMonitoring | Other | Feb 2026 | €71M |
| Neurent Medical | Series C | Feb 2026 | €63M |
| Vitestro | Series B | Mar 2026 | €60M |
| Uromems | Growth/Late | May 2026 | €52M |
| Exciva | Series B | Jan 2026 | €51M |
| FineHeart | Grant | Jan 2026 | €48M |
| Storm Therapeutics | Series C | Apr 2026 | €48M |
| NVision Imaging | Series B | May 2026 | €47M |
| IMU Biosciences | Other | Jun 2026 | €45M |
| Biorce | Series A | Feb 2026 | €44M |
Top investors
most active in H1 2026, by deal count- High-Tech Gründerfonds (HTGF)10 deals
- BioInnovation Institute6 deals
- Innovate UK5 deals
- Bayern Kapital4 deals
- better ventures4 deals
- European Investment Bank (EIB)4 deals
- IBB Ventures4 deals
- Mercia Ventures4 deals
- Octopus Ventures4 deals
- Venture Kick4 deals